跳至主要内容
临床试验/NCT05592327
NCT05592327尚未招募不适用

Citric Acid Passivation on Implant Abutments for the Prevention of Peri-implant Disease: a Randomized Controlled Clinical Trial

Universitat Internacional de Catalunya0 个研究点目标入组 36 人开始时间: 2022年11月3日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
36
主要终点
Biofilm quantification

研究概览

简要总结

The use of dental implants is a predictable procedure to replace the missing tooth with high rates of success and survival. In addition, placing the abutment on the same day as the implant surgery is a safe and biologically sound procedure to minimize bone loss and peri-implant inflammation. Although citric acid antibacterial coating has never been tested in vivo, recent in vitro data support its clinical use due to its antibacterial effect at the abutment level.

This prospective randomized controlled clinical trial aims to evaluate the microbiological and inflammatory profile of implant abutments coated with citric acid.

详细描述

The study population will consist on patients referred to the Department of Periodontology at Universitat Internacional de Catalunya for the replacement of missing teeth and who meet the following inclusion criteria will be included consecutively in the study.

5.3.1. Inclusion criteria

  • Patients with ≥18 years old.
  • Systemically healthy patients.
  • Patients with healthy periodontal status with a full mouth plaque index ≤ 20% (O'Leary, 1972) and full mouth bleeding index (Ainamo & Bay, 1975) before implant surgery.
  • Need for at least one dental implant in maxillary and mandibular partially posterior edentulous healed sites.

5.3.2. Exclusion criteria

  • Patients with some special conditions that could interfere surgical oral procedures.
  • Patients with non-treated periodontal disease.
  • Patients with uncontrolled systemic disease that could impair wound healing (i.e. Diabetes Mellitus).
  • Pregnant women.
  • Patients allergic to any metallic component of the materials.
  • Need for bone or soft tissue reconstruction simultaneous to implant placement.
  • Lack of primary stability during implant placement (i.e., insertion torque < 25 N, ISQ > 60)
  • Smokers ≥ 10 cigarettes per day.
  • Patients will be excluded from the study if they violate any of the criteria during the trial, as well as if they desire to withdraw the study or have any adverse reactions to the materials employed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with ≥18 years old.
  • Systemically healthy patients.
  • Patients with healthy periodontal status with a full mouth plaque index ≤ 20% (O'Leary, 1972) and full mouth bleeding index (Ainamo & Bay, 1975) before implant surgery.
  • Need for at least one dental implant in maxillary and mandibular partially posterior edentulous healed sites.

排除标准

  • Patients with some special conditions that could interfere surgical oral procedures.
  • Patients with non-treated periodontal disease.
  • Patients with uncontrolled systemic disease that could impair wound healing (i.e. Diabetes Mellitus).
  • Pregnant women.
  • Patients allergic to any metallic component of the materials.
  • Need for bone or soft tissue reconstruction simultaneous to implant placement.
  • Lack of primary stability during implant placement (i.e., insertion torque < 25 N, ISQ > 60)
  • Smokers ≥ 10 cigarettes per day.
  • Patients will be excluded from the study if they violate any of the criteria during the trial, as well as those that desire to withdraw the study or have any adverse reactions to the materials employed.

结局指标

主要结局

Biofilm quantification

时间窗: 12 weeks, 6 months, 1 and 3 years

The primary outcome measure will be the reduction of biofilm formation at the test abutments compared with the control abutments at the 12 weeks, 6 months, 1 year and 3 years. Biofilm formation over the retrieved abutments will be quantified by means of Illumina sequencing analysis

次要结局

  • Peri-implant disease incidence(1 and 3 years)
  • Protein expression markers(12 weeks, 6 months, 1 and 3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Javi Vilarrasa

Doctor

Universitat Internacional de Catalunya

相似试验